October 15, 2017 - By Clifton Ray
Analysts expect Guyana Goldfields Inc. (TSE:GUY) to report $0.10 EPS on November, 9.They anticipate $0.04 EPS change or 66.67% from last quarter’s $0.06 EPS. T_GUY’s profit would be $17.32M giving it 12.03 P/E if the $0.10 EPS is correct. After having $-0.03 EPS previously, Guyana Goldfields Inc.’s analysts see -433.33% EPS growth. The stock increased 0.42% or $0.02 on October 13, reaching $4.81. About 539,337 shares traded. Guyana Goldfields Inc. (TSE:GUY) has 0.00% since October 15, 2016 and is . It has underperformed by 16.70% the S&P500.
Among 3 analysts covering Egalet Ltd (NASDAQ:EGLT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Egalet Ltd had 10 analyst reports since November 4, 2015 according to SRatingsIntel. The stock of Egalet Corp (NASDAQ:EGLT) has “Market Outperform” rating given on Friday, July 14 by JMP Securities. Cantor Fitzgerald maintained the shares of EGLT in report on Friday, August 25 with “Buy” rating. Cantor Fitzgerald maintained it with “Buy” rating and $7.0 target in Monday, September 11 report. The stock of Egalet Corp (NASDAQ:EGLT) has “Buy” rating given on Friday, June 9 by JMP Securities. Cantor Fitzgerald maintained Egalet Corp (NASDAQ:EGLT) on Thursday, June 1 with “Buy” rating. Guggenheim maintained Egalet Corp (NASDAQ:EGLT) on Monday, August 14 with “Buy” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, June 13. The company was maintained on Monday, August 14 by Cantor Fitzgerald. The firm has “Buy” rating by Cantor Fitzgerald given on Wednesday, November 4. The firm earned “Buy” rating on Wednesday, June 7 by Cantor Fitzgerald. See Egalet Corp (NASDAQ:EGLT) latest ratings:
11/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $7.0 Maintain
25/08/2017 Broker: Cantor Fitzgerald Rating: Buy Maintain
14/08/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $7.0000 Maintain
14/08/2017 Broker: Guggenheim Rating: Buy New Target: $7.0000 Maintain
14/07/2017 Broker: JMP Securities Rating: Market Outperform Old Target: $15 New Target: $6 Maintain
13/06/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $8.0000 Maintain
09/06/2017 Broker: JMP Securities Rating: Buy New Target: $15.0000 Maintain
07/06/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $8.0000 Maintain
01/06/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $8.0000 Maintain
Egalet Corporation is a specialty pharmaceutical company. The company has market cap of $49.08 million. The Firm is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. It currently has negative earnings. The Company’s products include OXAYDO and SPRIX Nasal Spray.
It closed at $1.14 lastly. It is up 46.67% since October 15, 2016 and is downtrending. It has underperformed by 63.37% the S&P500.
Investors sentiment decreased to 0.71 in 2017 Q2. Its down 0.02, from 0.73 in 2017Q1. It fall, as 15 investors sold Egalet Corp shares while 16 reduced holdings. 12 funds opened positions while 10 raised stakes. 10.98 million shares or 9.28% less from 12.10 million shares in 2017Q1 were reported. National Bank & Trust Of America Corp De stated it has 0% in Egalet Corp (NASDAQ:EGLT). Tiverton Asset Llc stated it has 0.01% in Egalet Corp (NASDAQ:EGLT). 323,171 are held by Wasatch Inc. Highland Capital Mgmt Limited Partnership accumulated 119,520 shares. Royal Retail Bank Of Canada reported 33 shares. Advisory Svcs Net Lc invested in 1,835 shares. 80,100 were reported by Paloma Prtn Management Co. Brandywine Glob Invest Ltd Limited Liability Company holds 0% or 30,000 shares in its portfolio. Deutsche State Bank Ag reported 57,268 shares stake. Federated Investors Inc Pa stated it has 1.23M shares or 0.01% of all its holdings. California Public Employees Retirement Systems reported 28,500 shares or 0% of all its holdings. Bnp Paribas Arbitrage Sa holds 0% in Egalet Corp (NASDAQ:EGLT) or 38 shares. Bridgeway Cap Mgmt Inc holds 195,850 shares. Janney Montgomery Scott Lc accumulated 45,963 shares. Stifel Fincl reported 18,890 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.